Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines gibt neue Überlebensdaten aus Phase-3-Studien bekannt, die den Nutzen von ZIIHERA-haltigen Therapien bei HER2-positivem gastroösophagealem Krebs in der Erstlinienbehandlung untermauern

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines announced positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 study. The study evaluates ZIIHERA (Zanidatamab) combined with chemotherapy, with or without TEVIMBRA (Tislelizumab), for treating HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. These findings support the drug's potential as a first-line treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive topline results from Phase 3 study HERIZON-GEA-01.
  • ZIIHERA shows potential as a first-line treatment.
  • Combination therapy may enhance treatment efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute positive Topline-Ergebnisse der zweiten Zwischenanalyse (IA2) der Phase-3-Studie HERIZON-GEA-01 bekannt, in der ZIIHERA® (Zanidatamab) in Kombination mit einer Chemotherapie, mit und ohne TEVIMBRA® (Tislelizumab), als Erstlinienbehandlung bei HER2-positivem lokal fortgeschrittenem oder metastasiertem gastroösophagealem Adenokarzinom (GEA) u

Frequently Asked Questions

What are the results of the Phase 3 study HERIZON-GEA-01?

The Phase 3 study HERIZON-GEA-01 reported positive topline results for ZIIHERA.

What is ZIIHERA used for?

ZIIHERA is evaluated as a first-line treatment for HER2-positive gastroesophageal cancer.

What therapies were combined with ZIIHERA in the study?

ZIIHERA was combined with chemotherapy, with and without TEVIMBRA.

Who conducted the HERIZON-GEA-01 study?

The study was conducted by BeOne Medicines Ltd.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines ZIIHERA HER2-positive cancer Phase 3 study gastroesophageal adenocarcinoma
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →